ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Selcia has doubled its capacity to conduct carbon-14 radiolabeling projects in Ongar, Essex, England. The company says it has been preparing radiolabeled active pharmaceutical ingredients for customers with compounds in Phase I clinical trials since September 2010, after certification by British authorities. Drug companies create radiolabeled versions of developmental compounds for metabolism, mass-balance, and microtracer studies, Selcia notes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter